A primary physiological function of follistatin is the binding and neutralization of activin, a transforming growth factor-␤ family growth factor, and loss of function mutations are lethal. Despite the critical biological importance of follistatin's neutralization of activin, the structural basis of activin's binding to follistatin is poorly understood. The purposes of these studies were 1) to identify the primary sequence(s) within the N-terminal domain of the follistatin coding for activin binding, and 2) to determine whether activin binding to the native protein causes changes in other structural domains of follistatin.
pyridylethylation of Cys residues followed by N-terminal sequencing and amino acid analysis revealed that all of the Cys residues in follistatin are involved in disulfide bonds and lack reactive free sulfhydryl groups.
Specific ligands were used to probe the structural effects of activin binding on the other domains of the full-length molecule, comprised largely of the three 10-Cys follistatin module domains. F OLLISTATIN is a protein essential for life; loss of function mutants die shortly after birth (1) . Follistatin was discovered as an inhibitor of pituitary FSH secretion, and it was this biological activity that allowed the first purification of follistatin from porcine (2) and bovine (3) ovarian tissues. However, it was soon recognized (4, 5) that this activity of follistatin was due to the ability of the protein to bind and neutralize the biological activity of activin, a widely distributed member of the transforming growth factor-␤ (TGF␤) family of growth factors. Follistatin-bound activin is prevented from binding to cell surface activin receptors (6) , and follistatin-activin complexes bound to plasma membrane proteoglycans are internalized and then degraded (7) . Neutralization of activin bioactivity by follistatin(s) is the basis of a widespread autocrine/paracrine system that plays a major role in regulating activin's impact on organogenesis during development and organ remodeling in adulthood (8 -15) .
Despite the critical importance of follistatin's neutralization of activin, the structural basis of activin binding to follistatin is poorly understood. Follistatin is a monomeric glycoprotein translated from messenger RNAs generated by alternative splicing of transcripts of a single gene (16, 17) . Thus, isoforms of follistatin derive from transcription of five exons (follistatin-288 isoforms) or six exons (follistatin-315 isoforms). Posttranslational glycosylation and/or proteolytic processing of these two core proteins can generate additional follistatin isoforms. However, all follistatin isoforms have similar activin-binding characteristics (6, 18) .
Perhaps the most remarkable structural feature of follistatin is the large number of cysteine (Cys) residues (n ϭ 36) contained in this small, 32,000 -35,000 M r protein. Also striking is the presence of distinct structural domains, evident from the exon organization and primary sequence of follistatin (16, 17) , which are characteristic of mosaic proteins derived from exon shuffling during evolution. After removal of a 29-amino acid leader sequence, the mature protein contains 5 domains ( Fig. 1) : an N-terminal domain of 63 amino acids (a.a.), three 73-to 75-amino acid repeats of what has become known as the follistatin module (19 -21) , and, in follistatins derived from the splice variant in which all 6 exons are transcribed (follistatin-315), a highly acidic C-terminal domain of 27 a.a. encoded by exon 6. The 10-Cys follistatin module is a motif found in a number of primarily extracellular matrix proteins involved in cellular differentiation and growth (20, (22) (23) (24) (25) .
Most of what is known regarding structure-function relationships for follistatin derives from correlations of structural perturbations with changes in activin, heparan sulfate, or cell surface binding. Amino acid residues in the N-terminal domain have been associated with activin binding because the insertion of two a.a. between residues 2 and 3 resulted in loss of in vitro bioactivity and activin-binding activity of the mutated follistatin-315 (26) . The ability of follistatin to bind cell surface proteoglycans appears to be mediated by a heparan sulfate-binding region located within the first follistatin domain (27, 28) . Interestingly, a reduced affinity for heparan sulfate or cell surface binding correlates with the presence of the C-terminal domain (29, 30) . Currently, none of the follistatins has been crystallized, nor have their tertiary structures been described in sufficient detail to provide insights into the spatial arrangement of the various domains.
The current studies were undertaken to identify specific epitopes directly involved with activin binding and to determine whether activin binding to intact follistatin altered domain-specific antigenic epitopes located outside the N domain. We designed synthetic peptide mimotopes based on the 288-amino acid sequence common to all isoforms of follistatin as direct probes (31) to identify binding epitopes for activin A. Heparan sulfate or monoclonal antibodies were then used as site-specific probes to reveal structural changes elsewhere in the follistatin molecule after activin binding.
Materials and Methods Materials
Recombinant human activin A (lot 15365-36) and recombinant human follistatin-288 (preparation B4384) were provided by the National Hormone and Pituitary Program of the NIH. High specific activity radioiodide and tritiated heparin (SA, 0.51 Ci/g) were purchased from NEN Life Science Products (Boston, MA). Sequence grade chemicals were used for chemical modification, peptide synthesis, and protein sequencing. Preformed linear gradient SDS gels for electrophoresis of proteins were purchased from Pharmacia. X-OMAT film obtained from Fuji Photo Film Co. Ltd. (Tokyo, Japan) was used for autoradiography. Figure 1 shows the peptides synthesized and the positions of the follistatin sequences they represent within the native protein. Synthetic peptides were designed to 1) represent the entire N domain (residues 1-63) for mapping the activin-binding site, 2) represent the heparan sulfate-binding site (27) , 3) represent the human-specific antigenic epitope of human follistatin (a.a. 168 -178), and 4) represent intra-Cys FIG. 1. Schematic representation of human follistatin showing location of mimotopes synthesized and screened for activin binding or used to generate site-specific monoclonal antibodies. The domain organization shown is based upon the exon structure of the follistatin gene, in which each domain is coded by 1 of the 6 exons of the gene. Domains I, II, and III are follistatin module sequences and have been aligned based upon the positions of the 10 conserved cysteine residues within these domains (vertical dashes).
Peptide synthesis and sequencing
sequences from each of the 10-Cys follistatin module domains of the follistatin-288 core protein. Peptides were also used to generate sitedirected monoclonal antibodies for use as structural probes of the Ctermini of follistatin-288 and follistatin-315. Progressive N-terminal truncations were introduced in the two peptides identified as containing activin-binding epitopes.
All peptides were prepared at the Peptide Core Facilities of the Reproductive Endocrine Sciences Center at Massachusetts General Hospital by solid phase synthesis using F-moc chemistry. The peptides were purified by reverse phase HPLC, and mass spectroscopy was used to verify the sequences and confirm peptide homogeneity.
Evaluation of free sulfhydryl groups in peptide mimotopes
The presence of free sulfhydryl groups on Cys residues of the peptide mimotopes was evaluated using Ellman's reagent (32) purchased from Pierce Chemical Co. (Rockford, IL). Peptides were dissolved initially in 0.1 m acetic acid to 10 mg/ml and then further diluted to 1 mg/ml (0.33-0.94 mm) with Ellman's reagent solution (0.1 m sodium phosphate, pH 8.0). Two hundred and fifty microliters of each of the peptides or assay standard (cysteine hydrochloride monohydrate, 0.25-1.5 mm) were tested in duplicate following the protocol recommended by the manufacturer.
Generation of monoclonal antibodies
The monoclonal antibody recognizing follistatin module domain II was generated in mice immunized with recombinant human follistatin-288 as previously described (33, 34) . Monoclonal antibodies against follistatin module domain III and the C-terminal domain were generated against synthetic peptides representing amino acid residues 274 -287 and 300 -315, respectively. Mice were immunized with protein or synthetic peptide-BSA conjugates emulsified in Freund's complete adjuvant (Sigma, St Louis, MO). Booster immunizations were composed of protein or peptide conjugated to BSA in Freund's incomplete adjuvant emulsifants. Both primary and booster immunizations were administered sc. After achieving suitable serum titers, spleen cells were harvested and fused with SP2/O myeloma cells obtained from the American Type Culture Collection (Manassas, VA). Hybridomas were selected by standard dilution cloning and enzyme immunoassay methods. Monoclonal antibodies were purified using protein G affinity chromatography from ascites fluid generated from pristane-primed mice inoculated ip with 5 ϫ 10 6 hybridoma cells. Harlan Laboratories, Inc. (Indianapolis, IN), generated and harvested the ascites fluids.
The use of mice in these studies was performed in compliance with NIH guidelines. Experimental procedures were reviewed and approved by an internal review board for the use of animal resources. Animals were housed and cared for in American Association for Accreditation of Laboratory Animal Care-accredited facilities operated by the Massachusetts General Hospital or Harlan Laboratories.
Solid phase binding assays
These assays were used to identify and refine activin, heparin, and antibody-binding epitopes. Follistatin peptides or follistatins were coated onto Immulon-4 enzyme-linked immunosorbent assay (ELISA) plates (Dynex Technologies, Chantilly, VA) by incubating 100 l of the appropriate solution at 4 C overnight. Follistatin peptides were initially dissolved in 0.1 m acetic acid to 10 mg/ml and then were diluted with 0.1 m sodium bicarbonate to 0.3, 1, 3, 10, 30, or 100 g/ml. Native follistatin was coated in a similar fashion using a 0.2 g/ml solution. Nonspecific binding sites on ligand-coated (peptide or follistatin) plates were blocked by incubation with 200 l of a blocking solution (PBS containing 0.05% gelatin and 0.05% Tween-20) at room temperature for 2 h. Binding of [
125 I]activin, [ 3 H]heparin, or monoclonal antifollistatin IgG was determined by incubating these probes in a total volume of 200 l in ligand-coated or control wells at room temperature for 4 h with gentle shaking. After incubation, unbound probes were decanted, and the plates were washed three times with PBS-0.05% Tween-20 to reduce nonspecific binding.
Bound [ 125 I]activin was measured by direct counting of the wells (inserted into 12 ϫ 75-mm plastic tubes) in a ␥-counter. Tritiated heparin bound to peptide or follistatin was measured by submerging washed wells in 10 ml liquid scintillation fluid in a 20-ml glass scintillation vial and were counted in a ␤-counter (Beckman Coulter, Inc., Los Angeles, CA). Bound antibody was measured with an ELISA reader (405 nm absorbance) after sequentially incubating with an antimouse IgG-alkaline phosphatase conjugate (Pierce Chemical Co.; 1:4000 dilution of conjugated antibody) and then a p-nitrophenyl phosphate substrate (Pierce Chemical Co.; 2.7 mm solution).
[ 125 I]Activin was prepared using lactoperoxidase and was purified by gel electrophoresis as previously described (35) . The specific activity of the [
125 I]activin was approximately 30 Ci/g based upon the method of Greenwood and Hunter (36) .
Additionally, a solid phase sandwich-type assay was used to examine the effects of activin on follistatin module domains I and II. Follistatin-288 in the absence or presence (5 and 50 ng/ml) of activin was allowed to bind at room temperature for 12 h to the capture monoclonal antibody, 7FS30, coated on the bottom of ELISA wells. Unbound follistatin was removed by washing. Tritiated heparin, the detection probe for follistatin module I, was added and incubated at room temperature for an additional 3 h to allow its binding to follistatin (free or activin-bound) captured by the solid phase antibody. The wells were then washed to remove free tritiated heparin, and the amount of follistatin-bound tritiated heparin was measured by counting using liquid scintillation fluid and a ␤-radiation counter. This basic sandwich-type assay format was also employed in a modified form using solid phase capture antibody covalently coupled to paramagnetic particles and a detection antibody conjugated to dimethylacrydinium ester. In this modification, bound reagents were separated from free using magnetic tube racks, and the chemiluminescent detection antibody was measured in a Ciba-Corning Magic Light Analyzer II (Chiron Corp., Walpole, MA).
Determination of follistatin peptide coating efficiency
The amount of peptide actually adsorbed to the microtiter wells was measured to determine the mass of peptide mimotopes used in each solid phase assay. Microtiter wells (10 wells/determination) were coated with peptide (3.29 -9.43 m peptide; see Table 1 ) as described above for the preparation of solid phase assay plates, then washed 3 times with PBS to remove unbound peptides. Eighty microliters of 0.5 m NaOH were added to each well, and the plates were incubated at room temperature with constant shaking for 1 h. Solubilized peptides from 10 wells were pooled, the pH was neutralized with concentrated HCl, and total peptide was determined using a dye-ligand protein assay kit (MicroBCA, Pierce Chemical Co.) and BSA as the protein standard.
To validate the results obtained by protein assay, peptides on microtiter wells were also quantitated by amino acid analysis. For these experiments, 80 l 6 m HCl were added to each well after the PBS wash procedure. Microtiter plates were sealed with plastic tape and incubated at 60 C for 4 h to elute and partially hydrolyze the adsorbed peptides. Acid eluates from 10 wells were pooled, hydrolyzed to completion at 110 C for 24 h in vacuo, and subjected to amino acid analysis (model 6300 analyzer, Beckman Coulter, Inc., Hialeah, FL).
Pyridylethylation of follistatin
To probe for free sulfhydryl groups within follistatin, the sulfhydrylreactive reagent vinylpyridine was used for derivatization of native 
Ligand blotting
SDS-PAGE and LIGAND blot analysis were performed as previously described (37) . X-Ray film (X-OMAT, Eastman Kodak Co., Rochester, NY) was exposed to the dried nitrocellulose blots for 3-7 days at Ϫ80 C.
Results

Activin binding to synthetic mimotopes
The ability of recombinant human activin A to bind directly to peptides representing linear sequences from human follistatin is summarized in Fig. 2A . Nonspecific binding by each of the ligands was monitored by inclusion of two types of controls in each binding experiment. Control 1 represented binding to microtiter wells containing no solid phase test peptide, but otherwise prepared identically to wells coated with synthetic peptide mimotopes. Control 2 represents binding of ligands to plates coated with an irrelevant synthetic peptide (R-K-G-Y-S-R-K-G-F-D-C; from an enzyme unrelated to follistatin) rather than synthetic fragments of human follistatin. Activin bound to only two synthetic fragments, follistatin-(1-26) and follistatin-(44 -59), from the N-terminal domain (a.a. 1-63). Under similar experimental conditions, no activin binding was observed to synthetic peptides representing epitopes within the follistatin module domains I, II, and III. Also shown in Fig. 2 is the mapping of tritiated heparin (Fig. 2B ) and monoclonal antibody 7FS30 (Fig. 2C ) using this series of synthetic peptides. Heparin binding mapped to separate epitopes within the N-terminal domain and follistatin module domains I, respectively. Heparin binding to the a.a. 74 -86 fragment replicates the previously identified heparin binding site (27) . The monoclonal antibody 7FS30 bound only to the amino acid 168 -178 fragment within the follistatin module domain II.
Although many of the peptides tested contain odd numbers of Cys residues, all were fully oxidized, as no free sulfhydryl groups were detected using Ellman's reagent (data not shown). Thus, misidentification of activin-binding mimotopes due to disulfide bonding between Cys residues in the solid phase peptides and Cys in activin itself is unlikely.
Because relatively low affinity interactions (nonspecific protein-protein or protein-matrix binding) can be detected using small synthetic peptides as solid phase ligands, the ability of native follistatins to block activin binding to solid phase peptide was used to further define the specificity of activin binding to the two putative follistatin mimotopes identified in Fig. 2 . Follistatin-activin complexes (0.36 nm activin/2.9 nm follistatin-288 or 0.36 nm activin/3.1 nm follistatin-315) were incubated with solid phase follistatin-(1-26) (197 pmol/well) or follistatin-(44 -59) (334 pmol/well) for 4 h; under these conditions the follistatin-activin complexes do not dissociate (35) . The binding of [ 125 I]activin that had been preincubated with BSA only for 1 h at room temperature was tested using BSA-coated wells (nonspecific control, bar 1) or using peptide mimotope-coated wells (positive controls, bars 2 and 5). As shown in Fig. 3 , the binding of [ 125 I]activin to the synthetic follistatin epitopes was completely blocked after coupling with native follistatins. Thus, the binding of activin to follistatin-(1-26) and follistatin-(44 -59) appeared to rely upon the same binding regions involved in its binding to native follistatins.
Determination of follistatin peptide coating efficiency
Ligand binding to peptide a.a. 1-26, 44 -59, 74 -86, and 168 -178 (Figs. 2 and 3) indicates the presence of these peptides on the microtiter plates. However, the absence of ligand binding can represent either the inability of the peptide mimotope to bind ligand or the inability of the peptide to adsorb to the microtiter plate. To distinguish between these two possibilities and to allow the interpretation of negative binding data, the coating efficiency for each of the peptides tested was determined. Two methods were used to measure solid phase peptides. An improved commercial dye-ligand protein assay was used with BSA protein calibrators to quan- titate peptide removed from microtiter wells with 0.5 m NaOH. Response curves generated from dilutions of the solubilized solid phase peptides were linear and parallel to each other as well to as a BSA reference curve, allowing quantitative comparisons (data not shown). The plating efficiency (percentage of peptide concentration used to coat the microtiter plate wells) calculated for each peptide is summarized in Table 1 . Plating efficiencies based on amino acid analysis of solid phase peptides subjected to acid hydrolysis in the microtiter wells is also summarized in Table 1 . These results indicate that despite very large differences (70-to Ͼ100-fol) with respect to ligand binding (Fig. 2) , all of the peptide mimotopes were present in closely equivalent amounts (differences Ͻ2-fold).
Refinement of N-terminal peptide binding sequences
Specific activin binding to two nonadjacent, linear sequences (Figs. 2 and 3 ) indicated that there may be two distinct activin-binding epitopes (a.a. 1-26 and a.a. 44 -59) located within the N domain. To define these activin-binding mimotopes more precisely, a series of N-terminal truncated peptides was synthesized (Tables 2 and 3 ). Each series of peptides successively truncated at the N-terminus was directly tested as solid phase ligands for their ability to bind activin. As determined by direct measurement of solid phase peptides (data shown in Fig. 4, insets) , N-terminal truncation did not significantly alter the ability of the peptide to stick to the microtiter wells. Figure 4A summarizes the results of mapping the binding of activin to follistatin-(1-26). Because follistatin-(1-26) and follistatin-(3-26) are equipotent activinbinding peptides, amino acid residues 1 and 2 of follistatin are not required for activin binding. However, none of the peptides truncated beyond a.a. 3-26 were able to bind activin, indicating that a.a. 3-5 of follistatin are essential for the binding activity of follistatin- . Figure 4B summarizes the mapping of the follistatin-(44 -59) mimotope. Removal of three a.a. from the N-terminus did not significantly affect [
125 I]activin binding. However, the subsequent deletion of a.a. 46 -47 resulted in a complete loss of [
125 I]activin binding, suggesting that those two a.a. are critical to activin binding to this mimotope. As this potential epitope had not been previously identified, an additional control was prepared by synthesizing a full-length (a.a. 44 -59) peptide with a scrambled sequence of the identical amino acid composition (Table 3 ). This peptide (scrambled amino acid 44 -59 sequence; Fig. 4B ) was inactive, supporting the specificity of the native sequence for activin.
Activin binding to chemically modified native follistatins
The binding of activin to synthetic fragments of follistatin indicates that at least two separate regions are involved in the binding reaction. However, binding to synthetic peptide mimotopes provides little insight into the conformational requirements, if any, of the native protein to allow these epitopes to interact in the binding of activin to native follistatin. Hence, follistatin-288 was unfolded by reduction of Cys residues to determine whether the linear epitopes, follistatin-(3-26) and follistatin-(46 -59), bind activin in linearized native follistatin or constitute a conformation-dependent binding site(s) within the N-terminal domain. Ligand blotting ([ 125 I]activin) after SDS gel-electrophoresis of reduced or unreduced follistatin-288 was used to assess the ability of activin to bind epitopes within the unfolded protein. As shown in Fig. 5 , activin binding to the complete 288-amino acid follistatin depends on the disulfide bonding of the protein. The lower limit of detection by ligand blotting was approximately 1 ng/lane. No activin binding could be detected when 20 ng reduced follistatin were loaded, and the amount of activin binding was near the limit of detection when the gels were deliberately overloaded with 100 ng follistatin/lane. It can be estimated from these considerations that reduction of the disulfide bonds resulted in at least a 99% loss of activin binding.
Pyridylethyl derivatization and N-terminal sequencing of follistatin
The Cys residue at position 3 is part of an activin-binding mimotope identified herein (Fig. 4) . Its importance is also suggested by loss of function mutants created by amino acid insertions between residues 2 and 3 of follistatin (26) . This Cys could be part of a disulfide bond in the native protein, or it could be present in an unbonded, reduced state. If Cys-3 is reduced in the native protein, its free sulfhydryl group might participate in postbinding reactions between activin and follistatin, explaining the essentially irreversible behavior of the follistatin-activin complex (35) . Thus, N-terminal composition and sequence analyses were performed after reacting follistatin-288 with 4-vinylpyridine to specifically derivatize free sulfhydryls (38, 39) .
As shown by the compositional analysis in Fig. 6 , the pyridylethyl Cys residue eluting at 51 min in the reduced vinylpyridine-treated control preparation was absent from the derivatized native follistatin. To determine the state of the sulfhydryls within the N-terminal 3-26 binding epitope precisely, each preparation was subjected to Edman microsequence analysis through 15 cycles. Phenylthiohydantoins representing pyridylethyl Cys, eluting between Tyr and Pro by on-line HPLC, were observed at positions 3 and 13 of the reduced, pyridylethylated control sample. No pyridylethyl Cys peak was found at either position in the pyridylethylated native preparation (Fig. 7) . Hence, Cys residues in native follistatin, including those at the active N-terminus, are present in the disulfide-bonded form and appear to be unavailable for covalent cross-linking with activin ligand.
Effects of activin binding on antigenic epitopes located in the nonactivin-binding domains of follistatin
To determine whether activin binding influences the conformation of the nonactivin-binding domains, probes specific for epitopes located in each of the three 10-Cys follistatin module domains or in the C-terminal domain were used before and after activin was bound to follistatin-288 or follistatin-315.
Tritiated heparin was used as a probe for the heparan sulfate-binding site located in domain I (Fig. 2B) . Domain II was probed using a monoclonal antibody, 7FS30, specific to the 168 -178 sequence (Fig. 2C) . Activin-induced changes in follistatin module domains I and II were probed simultaneously using a sandwich-type immunoassay composed of solid phase antibody bound to plastic plates to capture follistatin and the tritiated heparin to detect the antibody-bound protein. The activin concentrations tested ranged from physiological (40) to slightly greater than a 2-fold molar excess relative to the concentration of follistatin. A full range of follistatin doses was examined so as to detect either competitive-or noncompetitive-type effects on probe binding. However, as shown in Fig. 8 , the response curves (which require binding of both probes to follistatin) were superimposable. Thus, activin binding did not impair follistatin recognition by specific probes to either domain I or II.
In contrast, activin binding resulted in dramatic changes in antigenic epitopes located within domains III and C. These changes were identified in sandwich-type immunoassays again using the 7FS30 monoclonal antibody conjugated to paramagnetic particles to capture follistatin. Domain-specific epitopes were detected and quantitated using dimethylac- ridinium ester-coupled monoclonal antibodies generated against synthetic peptides representing epitopes in domain III (a.a. 274 -287) or in the C domain (a.a. 300 -315). As shown in Fig. 9 , activin binding to follistatin resulted in a marked decrease in recognition by the monoclonal antibody directed against the domain III epitope. Assay conditions were optimized to provide sensitive detection of follistatin (0.3 nm) and a reasonable dose-response working range (10-fold). These assay conditions allowed the testing of excess activin concentrations ranging from about 2-fold (7 nm activin/3 nm follistatin) to about 20-fold (7 nm activin/0.3 nm follistatin). Because the effects of activin binding could have been due to alteration of follistatin conformation or steric hindrance of probe binding, detailed dose-response curves for follistatin were examined.
Activin binding also effected changes in the follistatin-315-specific C domain. As shown in Fig. 10 , activin binding enhanced antibody binding to the C domain epitope. This detailed analysis of follistatin response curves generated under optimal assay conditions indicated that enhanced binding could be detected even at a 1:1 molar ratio of activin to follistatin. This observation suggests conformational changes associated with activin binding, resulting in a more favorable C domain antigenic epitope, either through higher affinity recognition or an enriched ensemble of favorable conformers among the population of follistatin-315 molecules.
Discussion
The most striking structural features of follistatin are its exon-based domain organization and the large number of Cys residues (36) present in this relatively small, 32,000 -35,000 M r , activin-binding protein (16, 17) . Given that the bioactivity of follistatin is a critical physiologically function, as evidenced by the lethal nature of loss of function mutations (1), surprisingly little has been reported delineating the structural basis for the ability of follistatin to bind activin and related TGF␤ ligands. Site-directed mutagenesis studies reported by Inouye et al. (26) identified a region located at the far N-terminus of follistatin that was critical for its binding and neutralization of activin. Our current findings expand earlier evidence (26) that activin binding is lost upon reduction of the disulfide bonding of the native follistatin protein, suggesting that the primary and secondary structures of the protein alone cannot assemble a functional activin-binding site. However, as reported here, the primary sequence does encode information necessary to bind activin. Using a series of synthetic peptide mimotopes, we identified activin binding by two linear sequences located within the N-terminal domain and separated by a lengthy nonactivin-binding interCys sequence. Correlating the removal of a.a. from longer sequences with changes in the ability of the peptides to bind activin identified these mimotopes, follistatin-(3-26) and follistatin-(46 -59).
The first activin-binding epitope predicted by mimotope binding data is located in the same region of follistatin previously identified by site-directed mutagenesis as important for activin binding based upon insertion of a.a. between residues 2 and 3 (26) . The second epitope, predicted to be located between a.a. 46 and 59, is newly identified in the current work. Each of these activin-binding epitopes are completely contained within inter-Cys sequences of the Nterminal domain common to follistatin-288 and -315.
Synthetic peptide mimotopes, being relatively small and unconstrained by tertiary or quaternary structure, are able to adopt multiple conformations (41, 42) . Thus, the current data demonstrate that properly folded native follistatin can display two activin-binding epitopes in the N-terminal domain. Because reduced native follistatin has no activin-binding activity (see below), it appears that the predicted activinbinding epitopes are not folded properly when the disulfide bonding of the intact protein is disrupted. Alternatively, the epitopes in the reduced protein may express the conformation necessary for activin binding, but a such a low affinity that it can only be detected in in vitro settings where excess peptide is available or when brought together by the disulfide-mediated folding of the native protein to produce a high affinity site of juxtaposed epitopes. The small amount of activin binding seen to reduced follistatin when overloaded gels were examined in Fig. 6 might support this alternative, but that small amount of activin binding could also reflect residual unreduced follistatin on the blot.
Currently, no conformational or three-dimentional studies of follistatin have been reported. Thus, we cannot be certain that the activin-binding epitopes predicted by the peptide mimotopes are folded into a complete activin-binding site by disulfide bonding of the native protein. It is possible that additional activin-binding epitopes exist within other domains of follistatin. These may be topographical sites composed of individual residues from several regions or linear sequences not represented by the probes used in this study.
One of the predicted activin-binding epitopes, 3-26, contains a Cys residue (a.a. 3). Thus, two alternative mechanisms could explain the loss of activin binding after the reduction of native follistatin. First, this loss could be due to conformational consequences of breaking disulfide bonds in a highly folded protein. Alternatively, if Cys-3 is not disulfide bonded in the native protein, reducing conditions could prevent the free sulfhydryl group from forming a disulfide bond with activin. The current studies rule out the second alternative, because we determined that all of the Cys residues, including Cys-3, are disulfide bonded in native follistatin-288. These observations together with the identification of two activin-binding sequences within the N-terminal domains suggest that the disulfide bond-dependent folding of the N-terminal domain assembles the activin-binding site.
The function of the three 10-Cys follistatin module domains remains unknown. No association has been reported between activin binding and the presence of similar follistatin module domains in numerous extracellular proteins (20, (22) (23) (24) (25) . Although our studies were not designed to screen the entire follistatin protein sequence for activin binding, none of the synthetic peptides representing sequences outside the N-terminal domain was able to bind activin directly. Thus, rather than contributing directly to activin binding, the role of the 10-Cys follistatin module domains may be 1) strictly structural, providing the scaffolding necessary for the proper orientation of the activin-binding site or for disulfide bonddependent assembly of the activin-binding site; 2) functional in an indirect manner, influencing activin binding by allosteric effects or by defining the orientation or alignment of those regions directly contacting activin; or 3) functional in a direct, albeit currently undefined, manner to stabilize the bound activin-follistatin complex, which is extremely stable under physiological conditions (35) .
Insight into interactions between the N-terminal domain and other domains is provided by our findings using heparin and monoclonal antibody probes in conjunction with activin binding. An important structural role for follistatin module domain I in maintaining a properly assembled activin-binding site in the N-terminal domain was suggested by reports (28) that heparin binding, localized to this region (27) , reduces the affinity of follistatin for activin. However, we observed that 1) activin cannot bind to the heparin-binding site located in domain I [follistatin 77-89)]; and 2) activin and heparin bind simultaneously despite overlapping epitopes in the first 26 a.a. of the N-terminal domain. In fact, binding of ligand probes for domains I (heparin) and II (antibody 7FS30) to native follistatin in the presence of activin suggests minimal interaction between the N-terminal domain and domains I and II.
In contrast, the effects of bound activin on antibody binding by segments of domains III and C strongly suggest interactions between these domains and the N-terminal domain. This observation may reflect steric effects of the bound activin molecule or conformational changes introduced by the binding process that alter the presentation of antigenic epitopes on follistatin domain III and the C-terminal domain. Steric effects of activin binding, such as epitope masking, could explain the effects observed in Fig. 9 , but not those seen in Fig. 10 . In this context it is of interest to note the presence of a thioredoxin/protein disulfide isomerase consensus sequence (43, 44) in both the N-terminal (a.a. 59 -63) and domain III (a.a. 237-241). These Cys pairs, although fully oxidized in native follistatin, could result in a reshuffling of the disulfide-bonding structure (45) upon activin binding, in FIG. 9 . Activin binding eliminates a follistatin monoclonal antibody recognition epitope in domain III. A follistatin monoclonal antibody was generated using follistatin-(274 -287) and labeled with dimethylacridinium ester (DMAE) to probe for activin effects on domain III. Labeled antibody was incubated with follistatin-288 or follistatin-315 in the absence or presence of activin (Ͼ2-fold molar excess relative to follistatin) for 12 h at 4 C. The DMAE antibody-bound follistatin was captured by a domain II-directed monoclonal antibody (7FS30) conjugated to magnetic particles and measured by a Luminometer. Data (relative light units) are means of duplicate determinations.
FIG. 10.
Activin binding enhances antigenicity of the C domain epitope recognized by a monoclonal antibody directed against follistatin-(300 -315). The follistatin-315-specific antibody was labeled with dimethylacridinium ester (DMAE) for detection and was allowed to bind follistatin-315 in the presence or absence of various concentrations of activin. The antibody-follistatin complex was then captured by a magnetic particle-antibody conjugate as described in Fig.  9 . Data points are means of duplicate determinations. Shifting of the response curves to the left in the presence of increasing concentrations of activin reveals an enhancement of follistatin-315-specific antibody binding to the C domain.
turn mediating conformational changes within the follistatin protein. The role, if any, of these Cys pairs during the activininduced conformational changes implied by our data is an important subject for future investigation.
Our studies provide new insights into the structure-function relationships of follistatin. However, an understanding of the complex nature of the activin-binding site is still far from complete. With this goal in mind, the linear activinbinding epitopes we identified using synthetic peptides represent precise targets for mutagenesis to generate follistatins with altered activin-binding properties. Recognition of these sequences will also aid in the interpretation of effects of mutations made to other regions of follistatin. Finally, synthetic peptides incorporating these linear activin-binding epitopes are candidates for the development of follistatin mimetics for modulating follistatin and/or activin biological activities. 44 -59
